Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
by Zacks Equity Research
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
by Zacks Equity Research
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Catalyst (CPRX) Focused on Development of Pipeline Candidates
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
by Zacks Equity Research
A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales
by Zacks Equity Research
Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.
Key FDA Events to Watch Out for in Aug 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
Dow 30 Stock Roundup: Caterpillar, DuPont, MCD, P&G Beat
by Swarup Gupta
The Dow enjoyed a strong week of gains, riding on stellar earnings results.
AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
by Zacks Equity Research
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
by Zacks Equity Research
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK
by Zacks Equity Research
We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy
J&J Brightens Outlook: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and offered an upbeat outlook for the full year. However, it lagged our revenue estimate.
Company News for July 19, 2017
by Zacks Equity Research
Companies in the News are: JNJ,BAC,UNH,CMG
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval
by Zacks Equity Research
Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.